Michael A Rossi - JoVE Visualize

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Bioorganic & Medicinal Chemistry Letters|December 23, 2008

Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activityYiwei Li, Jun Liang, Tony Siu, et al.

ACS Medicinal Chemistry Letters|March 18, 2016

Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDIJoseph E Pero, Michael A Rossi, Michael J Kelly, et al.

Bioorganic & Medicinal Chemistry Letters|May 4, 2017

Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain modelJoseph E Pero, Michael A Rossi, Hannah D G F Lehman, et al.

Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Bioorganic & Medicinal Chemistry Letters|December 23, 2008

Allosteric inhibitors of Akt1 and Akt2: discovery of [1,2,4]triazolo[3,4-f][1,6]naphthyridines with potent and balanced activityYiwei Li, Jun Liang, Tony Siu, et al.

ACS Medicinal Chemistry Letters|March 18, 2016

Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDIJoseph E Pero, Michael A Rossi, Michael J Kelly, et al.

Bioorganic & Medicinal Chemistry Letters|May 4, 2017

Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain modelJoseph E Pero, Michael A Rossi, Hannah D G F Lehman, et al.

Pageof 2